Inflammation
Review explores Lp(a)'s dual role in both driving and, in some contexts, dampening the inflammation behind atherosclerosis (Curr Atheroscler Rep 2024)
Original title: Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis
This review examines how Lp(a) contributes to atherosclerotic cardiovascular disease through inflammatory pathways, beyond its established role as an independent ASCVD risk factor. It describes how Lp(a) promotes inflammatory processes and interacts with cellular components to cause endothelial dysfunction and smooth muscle cell proliferation, while also highlighting a more complex, dual role in which Lp(a) can, under certain conditions, mitigate rather than instigate inflammation. The authors argue that this interplay between Lp(a) and inflammatory responses positions Lp(a) as a potential therapeutic target beyond simple concentration-lowering, and call for further investigation into these inflammatory mechanisms to inform novel approaches to managing and preventing ASCVD.
Original abstract
Purpose Of Review: The primary objective of this review is to explore the pathophysiological roles and clinical implications of lipoprotein(a) [Lp(a)] in the context of atherosclerotic cardiovascular disease (ASCVD). We seek to understand how Lp(a) contributes to inflammation and arteriosclerosis, aiming to provide new insights into the mechanisms of ASCVD progression.
Recent Findings: Recent research highlights Lp(a) as an independent risk factor for ASCVD. Studies show that Lp(a) not only promotes the inflammatory processes but also interacts with various cellular components, leading to endothelial dysfunction and smooth muscle cell proliferation. The dual role of Lp(a) in both instigating and, under certain conditions, mitigating inflammation is particularly noteworthy. This review finds that Lp(a) plays a complex role in the development of ASCVD through its involvement in inflammatory pathways. The interplay between Lp(a) levels and inflammatory responses highlights its potential as a target for therapeutic intervention. These insights could pave the way for novel approaches in managing and preventing ASCVD, urging further investigation into Lp(a) as a therapeutic target.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.